Earlier this summer, Pfizer halted global distribution of its smoking cessation drug, Chantix. A few weeks later, the company recalled over a dozen lots of the drug. Now, according to a Fierce Pharma article, the drugmaker is recalling all 0.5 mg and 1 mg lots across the country. The reason is the the drug was found to contain unacceptable levels of a specific nitrosamine, which can cause cancer over time with exposure to high levels. The drug was approved by the FDA 15 years ago, and saw nearly a billion in sales last year.
Pfizer Recalls All Chantix Nationwide
The recall is a precautionary measure taken after the medicine was found to contain a cancer-causing impurity.
Sep 23, 2021
Recommended
Recommended
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
